OBJECTIVE: Clozapine and olanzapine treatment has been associated with insulin resistance in non-obese schizophrenia patients. Much less is known regarding other agents such as quetiapine. The objective of this study was to compare matched olanzapine- and quetiapine-treated schizophrenia patients and normal controls on measures of glucose metabolism. METHOD: A cross-sectional comparison of quetiapine-treated and olanzapine-treated non-obese (body mass index < 30.0 kg/m2) schizophrenia subjects (DSM-IV) with matched normal controls using a frequently sampled intravenous glucose tolerance test and nutritional assessment was conducted from April 2002 to October 2004. Data from 24 subjects were included in the analysis (7 quetiapine, 8 olanzapine, 9 normal controls). RESULTS: There was a significant difference among groups for fasting baseline plasma glucose concentrations (p = .02), with olanzapine greater than normal controls (p = .01). The insulin sensitivity index (SI) differed significantly among groups (p = .039); olanzapine subjects exhibited significant insulin resistance compared to normal controls (p = .01), but there was no significant difference for quetiapine versus olanzapine (p = .1) or quetiapine versus normal controls (p = .40). SI inversely correlated with quetiapine dose (p = .0001) and waist circumference (p = .03) in quetiapine-treated subjects. Insulin resistance calculated by the homeostasis model assessment of insulin resistance (HOMA-IR) also differed significantly among groups (p = .03). The olanzapine group had a higher HOMA-IR level than normal controls (p = .01). There was a significant difference in glucose effectiveness (SG) among the groups (p = .049). SG was lower in the olanzapine group than in the quetiapine group (p = .03) and in the olanzapine group compared to normal controls (p = .049). CONCLUSIONS: Our findings are consistent with our previous report that nonobese olanzapine-treated subjects showed insulin resistance, measured by both HOMA-IR and SI, and reduction in SG. Studies that include larger samples, unmedicated patients, and varying durations of antipsychotic exposure are necessary to confirm these results.
OBJECTIVE:Clozapine and olanzapine treatment has been associated with insulin resistance in non-obese schizophreniapatients. Much less is known regarding other agents such as quetiapine. The objective of this study was to compare matched olanzapine- and quetiapine-treated schizophreniapatients and normal controls on measures of glucose metabolism. METHOD: A cross-sectional comparison of quetiapine-treated and olanzapine-treated non-obese (body mass index < 30.0 kg/m2) schizophrenia subjects (DSM-IV) with matched normal controls using a frequently sampled intravenous glucose tolerance test and nutritional assessment was conducted from April 2002 to October 2004. Data from 24 subjects were included in the analysis (7 quetiapine, 8 olanzapine, 9 normal controls). RESULTS: There was a significant difference among groups for fasting baseline plasma glucose concentrations (p = .02), with olanzapine greater than normal controls (p = .01). The insulin sensitivity index (SI) differed significantly among groups (p = .039); olanzapine subjects exhibited significant insulin resistance compared to normal controls (p = .01), but there was no significant difference for quetiapine versus olanzapine (p = .1) or quetiapine versus normal controls (p = .40). SI inversely correlated with quetiapine dose (p = .0001) and waist circumference (p = .03) in quetiapine-treated subjects. Insulin resistance calculated by the homeostasis model assessment of insulin resistance (HOMA-IR) also differed significantly among groups (p = .03). The olanzapine group had a higher HOMA-IR level than normal controls (p = .01). There was a significant difference in glucose effectiveness (SG) among the groups (p = .049). SG was lower in the olanzapine group than in the quetiapine group (p = .03) and in the olanzapine group compared to normal controls (p = .049). CONCLUSIONS: Our findings are consistent with our previous report that nonobese olanzapine-treated subjects showed insulin resistance, measured by both HOMA-IR and SI, and reduction in SG. Studies that include larger samples, unmedicated patients, and varying durations of antipsychotic exposure are necessary to confirm these results.
Authors: Vicki L Ellingrod; Stephan F Taylor; Gregory Dalack; Tyler B Grove; Michael J Bly; Robert D Brook; Sebastian K Zöllner; Rodica Pop-Busui Journal: J Clin Psychopharmacol Date: 2012-04 Impact factor: 3.153
Authors: Sun H Kim; Lilla Nikolics; Fahim Abbasi; Cindy Lamendola; James Link; Gerald M Reaven; Steven Lindley Journal: J Psychiatr Res Date: 2009-12-03 Impact factor: 4.791
Authors: David C Henderson; Xiaoduo Fan; Paul M Copeland; Bikash Sharma; Christina P Borba; Ryan Boxill; Oliver Freudenreich; Corinne Cather; A Eden Evins; Donald C Goff Journal: J Clin Psychopharmacol Date: 2009-04 Impact factor: 3.153
Authors: D C Henderson; X Fan; B Sharma; P M Copeland; C P Borba; R Boxill; O Freudenreich; C Cather; A Eden Evins; D C Goff Journal: Acta Psychiatr Scand Date: 2009-01-12 Impact factor: 6.392
Authors: David C Henderson; Xiaoduo Fan; Paul M Copeland; Bikash Sharma; Christina P Borba; Sharon I Forstbauer; Kate Miley; Ryan Boxill; Oliver Freudenreich; Corrine Cather; Anne E Evins; Donald C Goff Journal: Hum Psychopharmacol Date: 2009-04 Impact factor: 1.672
Authors: David C Henderson; Xiaoduo Fan; Bikash Sharma; Paul M Copeland; Christina P C Borba; Oliver Freudenreich; Corinne Cather; A Eden Evins; Donald C Goff Journal: J Psychiatr Pract Date: 2009-07 Impact factor: 1.325
Authors: Jonathan M Meyer; Vicki G Davis; Donald C Goff; Joseph P McEvoy; Henry A Nasrallah; Sonia M Davis; Robert A Rosenheck; Gail L Daumit; John Hsiao; Marvin S Swartz; T Scott Stroup; Jeffrey A Lieberman Journal: Schizophr Res Date: 2008-02-06 Impact factor: 4.939